Wind, or the initial lack thereof, didn’t stop the Lincoln City Fall Kite Festival on Saturday afternoon. Over 50 kite performers and a few hundred audience members flocked to the beach to watch or ...

KITE & KEY MEDIA: Nuclear is the power source of the future ... and it has been for about 50 years. Could this time be different? In 1967, America expected to operate 1,000 nuclear power plants by the ...

Trump flags fly on the storefront display of Kligs Kites at Broadway at the Beach. Jason Lee [email protected] Bruce Kilgman was a fixture in the Grand Strand community. A co-founder of the beloved ...

Gilead Sciences' Kite Pharma has cut off a collaboration with Shoreline Biosciences, ending a research collaboration on off-the-shelf cell therapies that was valued at more than $2.3 billion. The deal ...

This content has been selected, created and edited by the Finextra editorial team based upon its relevance and interest to our community. PayPal was joined by General Catalyst, 8VC, Samsung Next, ...

The round, co-led by General Catalyst and PayPal Ventures, brings the San Francisco-based startup’s cumulative funding to $33 million, according to an emailed announcement on Tuesday. Formerly known ...

@2024 - All Right Reserved.

Paramount+ has revealed the list of titles heading to the platform throughout September, and you can feel the Fall chill in the air, with films like Friday the 13th, Scary Movie, Sleepy Hollow, The ...

Jeremy has more than 2000 published articles on Collider to his name, and has been writing for the site since February 2022. He's an omnivore when it comes to his movie-watching diet, so will gladly ...

An error has occurred. Please try again. With a The Portland Press Herald subscription, you can gift 5 articles each month. It looks like you do not have any active ...

AT SIX. AND NEW AT SIX. A KITESURFER RESCUED OFF GRAVES LIGHT AND A CHANCE ENCOUNTER SAVED HIS LIFE. LET’S GET TO NEWSCENTER 5 JOHN ATWATER. HE SPOKE WITH HIM. HE JOINS US LIVE FROM EAST BOSTON RIGHT ...

Gilead Sciences has become the latest pharma to strengthen its in vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. Integrating Interius into ...